Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers

Johnson & Johnson

Merck

Novo Nordisk

We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.

10 Drugs Selected for Medicare Price Reduction

Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.

Novartis (NVS) Announces Positive Long-Term Data on Leqvio

AbbVie

Eli Lilly

Amgen

AstraZeneca

Pfizer

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.

Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar

Regeneron Pharmaceuticals

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

Oncology Market's Huge Potential Puts These Stocks in Focus

August 28, 2023 — Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years in patients with atherosclerotic cardiovascular disease (ASCVD), increased risk of ASCVD or heterozygous familial hypercholesterolemia (HeFH)1. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam.

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Novartis' remibrutinib could be a game-changer for patients with chronic spontaneous urticaria. Estimates suggest the new drug could eventually top $1 billion in peak annual sales for Novartis.

Could This Medicine Be the Next Winner for Novartis?

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issued Sandoz Listing Prospectus published Proposed distribution of a dividend-in-kind of Sandoz shares to Novartis shareholders: one Sandoz share for every five Novartis shares and one Sandoz ADR for every five Novartis ADRs Sandoz Spin-off planned to occur on or around October 4, 2023 Basel, August 18, 2023 — Novartis today issued the invitation to an Extraordinary General Meeting (EGM) of Novartis shareholders, scheduled to take place on September 15, 2023, in relation to the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.

Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote

Vertex Pharmaceuticals

Vertex Pharmaceuticals' innovative potential in areas with unmet needs is proving to be a major strength. Novartis is shaking up its business in ways that should help it deliver much stronger returns in the future.

2 Excellent Stocks to Buy and Hold Forever

Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.

Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth

Chinook Therapeutics

Basel, August 11, 2023 — Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.

Novartis Completes Acquisition of Chinook Therapeutics

Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across urticaria disease activity scores 1 Patients on remibrutinib saw rapid improvement as early as 2 weeks after treatment initiation 1 Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including balanced liver function tests in active and placebo arms across both studies 1 Final (52 weeks) readout and submission in 2024; full data will be presented at upcoming medical meetings If approved, remibrutinib has the potential to become the first of a new class of chronic spontaneous urticaria (CSU) treatment in a decade, offering a simple and effective option for the 60% of patients uncontrolled by H1-antihistamines 2 Basel, August 09, 2023 — Novartis today announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d.

Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

BeiGene

Exelixis

Kura Oncology

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

PepsiCo

Many of Novartis' top drugs saw their revenue generation grow by double digits this year. PepsiCo did not see big drops in sales volume despite increasing its prices.

2 Stocks That Raised Their Guidance in July

B2Gold

Chevron

Park Electrochemical

Tyson Foods

Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the world seemingly poised for a massive conflict, market participants may want to seek the relative stability of dividend investing in proven enterprises.

The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos

Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.

Novartis AG To Spin-Off Sandoz Business In 4Q23

Novartis' exceptional lineup of medicines produced stellar results in Q2. The company's market-beating dividend looks to be sustainable.

Should Income Investors Buy This Blue Chip Stock?

After more than a decade of trading within a wide and volatile range, it looks like Novartis NYSE: NVS shares will move to a new high and sustain the move.

Can Novartis Move to New Highs and Sustain Them?

Novartis released its 2023 Q2 earnings this morning. The revised forecast reflects the robust demand for key products as well as the potential launch of new therapies in its pipeline.

Why Novartis Stock Spiked Today

Novartis ADRs jumped after the pharmaceutical firm raised its outlook, announced a stock buyback, and detailed spinoff plans.

Novartis Raises Guidance, and Announces Stock Buyback and Spinoff Plans

Novartis AG (NYSE:NVS ) Q2 2023 Earnings Conference Call July 18, 2023 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Jo Walton - Credit Suisse Emmanuel Papadakis - Deutsche Bank Emily Field - Barclays Graham Parry - Bank of America Michael Leuchten - UBS Tim Anderson - Wolfe Research Mark Purcell - Morgan Stanley Kerry Holford - Berenberg Steve Scala - Cowen Seamus Fernandez - Guggenheim Securities Naresh Chouhan - Intron Health Peter Welford - Jefferies Andrew Baum - Citi Simon Baker - Redburn Eric Le Berrigaud - Stifel Rajesh Kumar - HSBC Richard Parkes - BNP Paribas Operator Good morning and good afternoon and welcome to the Novartis Q2 2023 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be in a listen-only mode and the conference is being recorded.

Novartis AG (NVS) Q2 2023 Earnings Call Transcript

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

Novartis raised its guidance and announced the buybacks as the Swiss drugmaker reported second-quarter earnings, which topped Wall Street's expectations.

Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buyback

News for Novartis Stock (NVS)